The deals are part of Eli Lilly’s effort to expand into infectious disease research and development. Read More
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development. Read More



